

References for Tumour Marker Audit June 2011

1. Sturgeon, CM, Lai, LC, Duffy, MJ. Serum tumour markers, how to order and interpret them. *BMJ* ,2009;399: 852-858
2. NICE guidance 2010. Metastatic malignant disease of unknown primary
3. NICE 2011. The recognition and initial management of ovarian cancer
4. NHS Cancer screening programme 2009. Prostate cancer risk management programme. Information for primary care: PSA testing in asymptomatic men
5. American Society of Clinical Oncology 2006. Update of recommendations for use of tumour markers in GI cancer. *J Clin Oncol* 2006;24 :5313-5327
6. Wong,R and Cunningham,D. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. *J.Clin Oncol* 2008;26: 5668-5670
7. Price,C et al. Pre and post analytical factors that may influence use of PSA. *Ann.Clin. Biochem* 2001 ;38:188-216
8. Bridgewater, JA et al Comparison of clinical and Ca 125 responses in patients with epithelial ovarian cancer treated with Platinum or Paclitaxel *J.Clin Oncol* 1999; 17:501-508
9. Bridgewater, J Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary *Br.J Cancer* 2008;98 1425-1430
10. Dukes CE et al. Pre op CEA levels and survival in patients with Dukes B or C tumours. *N.Engl J Med* 1978;299:448-451
11. Chan,CH Novel mouse model for CEA based therapy. 2004. *Mol Ther*;9:775-85